Mega-dose sodium ascorbate: a pilot, single-dose, physiological effect, double-blind, randomized, controlled trial
Primary resultResult — go to the resultMean difference 891.5 95% CI - 2.1 to 1785.2Authors' conclusion
In patients with septic shock, mega-dose NaAscorbate did not significantly increase cumulative 24-h UO. However, it induced a significantly greater increase in UO and a greater reduction in vasopressor dose and SOFA score over time.
Study context
- Population
- Patients with septic shock within 24 h of diagnosis
- Participants
- 30 patients
- Comparison
- Single mega-dose NaAscorbate vs placebo
- NaAscorbaten = 15
- Placebon = 15reference
- Primary endpoint
- Total 24 h urine output (UO) from the beginning of study treatment
- Follow-up
- 24 h
Methodological detailspilot, single-dose, double-blind, physiological effect
- Pilot
- Single-dose
- Double-blind
- Physiological effect
Primary result
As reported in the abstract
Mean difference
891.5
95% CI - 2.1 to 1785.2
P = 0.051
By group
NaAscorbate vs Placebo
mean difference 891.5 (95% CI - 2.1 to 1785.2); P = 0.051
Secondary outcomes
Progressive cumulative urine output (UO) over time (linear mixed modelling)
- Greater over time with NaAscorbate
- P < 0.001
Vasopressor dose change over time
- Faster reduction with NaAscorbate
- P < 0.001
Sequential organ failure assessment (SOFA) score change over time
- Faster reduction with NaAscorbate
- P = 0.042
Other clinical outcomes
- No statistical difference
Safety
Sodium level over time
- Increased more over time with NaAscorbate
- P < 0.001
Hypernatremia and hemolysis
- Hypernatremia episodes in NaAscorbate
- 1
- Hemolysis episodes in NaAscorbate
- 1
Original publication
Mega-dose sodium ascorbate: a pilot, single-dose, physiological effect, double-blind, randomized, controlled trial. Crit Care. Published 12 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →